EBX-102 demonstrated proof-of-principle across multiple microbiome assessments, inflammatory biomarkers and clinical assessments, supporting its cont ...

TD Cowen analyst Marc Frahm has maintained their bullish stance on JANX stock, giving a Buy rating on October 31. Marc Frahm’s rating is ...

The IND supports the initiation of a phase 1 clinical trial, BL-M17D1-ST-101, to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of BL-M17D1 for the treatment of patients ...

Papadopoulos, Co-Director of Clinical Research at START San Antonio, principal investigator for the STC-15 Phase 1 study and lead author of the SITC presentation, said: "The ability to activate the ...

ClearPoint Neuro reported strong YoY growth in Q3, but the stock reacted negatively. Check out my recommendation for CLPT ...

J.P. Morgan analyst Hardik Parikh has maintained their bullish stance on VKTX stock, giving a Buy rating today. Hardik Parikh has given his ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

The primary objective of the OASIS trial is to assess the safety and tolerability of Imugene’s onCARlytics (CF33-CD19) when ...

Hypertension affects 1 in 8 adults aged between 20 and 40 years. The prevalence of hypertension among adults in India is ...

AstraZeneca and Eccogene revealed promising trial data on ECC5004, an oral GLP-1 receptor agonist for obesity, showing safety ...

Background: Statins are generally well tolerated, but some patients discontinue therapy secondary to adverse effects. Dosing a statin (rosuvastatin) every other day (EOD) may provide significant ...